Skip to main content

Advertisement

Log in

A new strategy for full-length Ebola virus glycoprotein expression in E.coli

  • Research article
  • Published:
Virologica Sinica

Abstract

Ebola virus (EBOV) causes severe hemorrhagic fever in humans and non-human primates with high rates of fatality. Glycoprotein (GP) is the only envelope protein of EBOV, which may play a critical role in virus attachment and entry as well as stimulating host protective immune responses. However, the lack of expression of full-length GP in Escherichia coli hinders the further study of its function in viral pathogenesis. In this study, the vp40 gene was fused to the full-length gp gene and cloned into a prokaryotic expression vector. We showed that the VP40-GP and GP-VP40 fusion proteins could be expressed in E.coli at 16 °C. In addition, it was shown that the position of vp40 in the fusion proteins affected the yields of the fusion proteins, with a higher level of production of the fusion protein when vp40 was upstream of gp compared to when it was downstream. The results provide a strategy for the expression of a large quantity of EBOV full-length GP, which is of importance for further analyzing the relationship between the structure and function of GP and developing an antibody for the treatment of EBOV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Ascenzi P, Bocedi A, Heptonstall J, Capobianchi MR, Di Caro A, Mastrangelo E, Bolognesi M, Ippolito G. 2008. Ebolavirus and Marburgvirus: insight the Filoviridae family. Mol Aspects Med, 29: 151–185.

    Article  CAS  PubMed  Google Scholar 

  • Audet J, Wong G, Wang H, Lu G, Gao GF, Kobinger G, Qiu X. 2014. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep, 4: 6881.

    Article  CAS  PubMed  Google Scholar 

  • Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu RH, Zhou B, Lu H, Kwilas SA, Hahn TJ, Kpamegan E, Hooper J, Carrion R, Jr., Glenn G, Smith G. 2016. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine, 34: 1927–1935.

    Article  CAS  PubMed  Google Scholar 

  • Bhattacharyya S, Hope TJ. 2011. Full-length Ebola glycoprotein accumulates in the endoplasmic reticulum. Virol J, 8: 11.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A. 2007. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol, 81: 6379–6388.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Das D, Jacobs F, Feldmann H, Jones SM, Suresh MR. 2007. Differential expression of the Ebola virus GP(1, 2) protein and its fragments in E. coli. Protein Expr Purif, 54: 117–125.

    Article  CAS  PubMed  Google Scholar 

  • Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, Kahnt J, Stroher U, Klenk HD, Volchkov V. 2004. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J, 23: 2175–2184.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Elliott LH, Sanchez A, Holloway BP, Kiley MP, McCormick JB. 1993. Ebola protein analyses for the determination of genetic organization. Arch Virol, 133: 423–436.

    Article  CAS  PubMed  Google Scholar 

  • Falzarano D, Krokhin O, Wahl-Jensen V, Seebach J, Wolf K, Schnittler HJ, Feldmann H. 2006. Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus. Chembiochem, 7: 1605–1611.

    Article  CAS  PubMed  Google Scholar 

  • Favier AL, Gout E, Reynard O, Ferraris O, Kleman JP, Volchkov V, Peyrefitte C, Thielens NM. 2016. Enhancement of Ebola virus infection via ficolin-1 interaction with the mucin domain of GP glycoprotein. J Virol, 90: 5256–5269.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Feldmann H, Jones S, Klenk HD, Schnittler HJ. 2003. Ebola virus: from discovery to vaccine. Nat Rev Immunol, 3: 677–685.

    Article  CAS  PubMed  Google Scholar 

  • Hartlieb B, Weissenhorn W. 2006. Filovirus assembly and budding. Virology, 344: 64–70.

    Article  CAS  PubMed  Google Scholar 

  • Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. 2001. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol, 75: 5205–5214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Johnson RF, Bell P, Harty RN. 2006. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J, 3: 31.

    Article  PubMed  PubMed Central  Google Scholar 

  • Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med, 11: 786–790.

    Article  CAS  PubMed  Google Scholar 

  • Kuhl A, Hoffmann M, Muller MA, Munster VJ, Gnirss K, Kiene M, Tsegaye TS, Behrens G, Herrler G, Feldmann H, Drosten C, Pohlmann S. 2011. Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells. J Infect Dis, 204 Suppl 3: S840–S849.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. 2008. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature, 454: 177–182.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee JE, Saphire EO. 2009a. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol, 4: 621–635.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee JE, Saphire EO. 2009b. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr Opin Struct Biol, 19: 408–417.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li D, Chen T, Hu Y, Zhou Y, Liu Q, Zhou D, Jin X, Huang Z. 2016. An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions. J Virol, 90: 8720–8728.

    Article  CAS  PubMed  Google Scholar 

  • Licata JM, Johnson RF, Han Z, Harty RN. 2004. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol, 78: 7344–7351.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Melito PL, Qiu X, Fernando LM, deVarennes SL, Beniac DR, Booth TF, Jones SM. 2008. The creation of stable cell lines expressing Ebola virus glycoproteins and the matrix protein VP40 and generating Ebola virus-like particles utilizing an ecdysone inducible mammalian expression system. J Virol Methods, 148: 237–243.

    Article  CAS  PubMed  Google Scholar 

  • Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Saikh KU, Heidebrink KD, Jahrling PB, Ulrich RG, Schmaljohn CS. 2003. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res, 92: 187–193.

    Article  CAS  PubMed  Google Scholar 

  • Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. 2002. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol, 76: 4855–4865.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. 2000. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine, 19: 142–153.

    Article  CAS  PubMed  Google Scholar 

  • Sanchez A, Kiley MP, Holloway BP, Auperin DD. 1993. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res, 29: 215–240.

    Article  CAS  PubMed  Google Scholar 

  • Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, Nabel GJ. 2006. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med, 3: e177.

    Article  PubMed  PubMed Central  Google Scholar 

  • Sullivan NJ, Peterson M, Yang ZY, Kong WP, Duckers H, Nabel E, Nabel GJ. 2005. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol, 79: 547–553.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sun Y, Carrion R, Jr., Ye L, Wen Z, Ro YT, Brasky K, Ticer AE, Schwegler EE, Patterson JL, Compans RW, Yang C. 2009. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology, 383: 12–21.

    Article  CAS  PubMed  Google Scholar 

  • Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. 2005. Virus-like particles exhibit potential as a panfilovirus vaccine for both Ebola and Marburg viral infections. Vaccine, 23: 3033–3042.

    Article  CAS  PubMed  Google Scholar 

  • Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. 1998. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A, 95: 5762–5767.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S. 2003. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A, 100: 15889–15894.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, Aman MJ, Bavari S. 2007a. Filovirus-like particles produced in insect cells: Immunogenicity and protection in rodents. Journal of Infectious Diseases, 196: S421–S429.

    Article  CAS  PubMed  Google Scholar 

  • Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. 2007b. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis, 196 Suppl 2: S430–S437.

    Article  CAS  PubMed  Google Scholar 

  • Ye L, Lin J, Sun Y, Bennouna S, Lo M, Wu Q, Bu Z, Pulendran B, Compans RW, Yang C. 2006. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology, 351: 260–270.

    Article  CAS  PubMed  Google Scholar 

  • Zampieri CA, Fortin JF, Nolan GP, Nabel GJ. 2007. The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity. J Virol, 81: 1230–1240.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This project was jointly supported by the National Science and Technology Major Project (2012ZX10004219 and 2012ZX10004403), the Presidential Fund of the Chinese Academy of Sciences and the Wuhan Key Laboratory on Emerging Infectious Diseases and Biosafety. We thank Dr. Guoliang Lu (Structural Biology of Viral Genome Replication, Wuhan Institute of Virology) for helpful advice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zhiming Yuan.

Additional information

ORCID: 0000-0002-3234-9616

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zai, J., Yi, Y., Xia, H. et al. A new strategy for full-length Ebola virus glycoprotein expression in E.coli . Virol. Sin. 31, 500–508 (2016). https://doi.org/10.1007/s12250-016-3845-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12250-016-3845-y

Keywords

Navigation